---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product comparison"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product comparison. Topics: Palazestrant: class, dosing, and OPERA-01 population; Palazestrant: phase 1/2 formulation, efficacy, and comparison with other estrogen receptor-targeting agents; Palazestrant: competing estrogen receptor-targeting products named by the sponsor; Elacestrant (Orserdu): indication, regimen, EMERALD efficacy, and warnings; 13 further topics. 17 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/product-comparison"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Palazestrant: class, dosing, and OPERA-01 population

> “Palazestrant is a next-generation, orally bioavailable complete estrogen receptor antagonist (CERAN) and SERD with potent activity targeting the ER”
> “Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant”
> “In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.”
> “OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.”
> “trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.1.2.14-2"></a>

### Palazestrant: phase 1/2 formulation, efficacy, and comparison with other estrogen receptor-targeting agents

> “All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.”
> “Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue”
> “At 120 mg/day, the median progression-free survival was 4.8 months (95% CI, 3.5–7.1) overall and 5.6 months (95% CI, 4.8–NE) among patients with cancers with ESR1 mutations.”
> “Additionally, unlike with other SERDs that have reported rates of up to 45% for bradycardia and 56% for photopsia, the incidence of bradycardia and photopsia was lower with palazestrant (9% and 5%, respectively)”
> “The CERAN/SERD mechanism of action of palazestrant is shared by fulvestrant, camizestrant and imlunestrant”
> “Elacestrant, which is a selective ER modulator (SERM) and SERD, does not completely shut down ER signaling due to being an partial agonist and was also more active in cancers harboring ESR1 mutations”
> “although a direct comparison has not been performed”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.14-3"></a>

### Palazestrant: competing estrogen receptor-targeting products named by the sponsor

> “Our lead product candidate, palazestrant, is a novel, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD)”
> “if we are successful in developing palazestrant, it may compete against existing products and product candidates in development, to the extent any such product candidates are approved, for the treatment of ER+ breast cancer, including fulvestrant, marketed as Faslodex® by AstraZeneca PLC”
> “camizestrant, marketed as ETCAMAH® by AstraZeneca PLC”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.1.2.14-4"></a>

### Elacestrant (Orserdu): indication, regimen, EMERALD efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer as detected by an FDA-authorized test” “with disease progression following at least one line of endocrine therapy” |
| Mechanism | “Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα).” |
| Recommended dosage | “The recommended dosage of ORSERDU is 345 mg taken orally with food once daily until disease progression or unacceptable toxicity occurs.” |
| Dosage forms and strengths | “Tablets: Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride) and 86 mg (equivalent to 100 mg elacestrant hydrochloride)” |
| Pivotal trial | “The efficacy of ORSERDU was evaluated in EMERALD (NCT03778931), a randomized, open-label, active-controlled, multicenter trial that enrolled 478 postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer of which 228 patients had ESR1 mutations.” |
| Prior therapy required | “Patients were required to have disease progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor.” |
| Median PFS, ESR1-mutated, ORSERDU (N = 115), months (95% CI) | “3.8 (2.2, 7.3)” |
| Median PFS, ESR1-mutated, fulvestrant or an aromatase inhibitor (N = 113), months (95% CI) | “1.9 (1.9, 2.1)” |
| PFS hazard ratio, ESR1-mutated (95% CI) | “0.55 (0.39, 0.77)” |
| Population without ESR1 mutations | “An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population.” |
| Warnings and precautions | “Dyslipidemia: ORSERDU may cause hypercholesterolemia and hypertriglyceridemia.” “Embryo-Fetal Toxicity: ORSERDU can cause fetal harm.” |

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Elacestrant: EMERALD progression-free survival in all patients and in patients with ESR1 mutation

> “PFS was prolonged in all patients (hazard ratio = 0.70; 95% CI, 0.55 to 0.88; P = .002) and patients with ESR1 mutation (hazard ratio = 0.55; 95% CI, 0.39 to 0.77; P = .0005).”
> “Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.1.2.14-6"></a>

### Elacestrant (Orserdu): wholesale acquisition cost at launch

| Strength | NDC | Pack size | WAC (as of date of commercial availability) | Date of commercial availability |
| --- | --- | --- | --- | --- |
| 86 mg | “72187010103” | “30 tablets” | “$7,123.00” | “2/3/2023” |
| 345 mg | “72187010203” | “30 tablets” | “$21,369.00” | “2/3/2023” |

Source: [Vermont Attorney General Orserdu report (2023)](https://ago.vermont.gov/sites/ago/files/2023-11/VT-high-cost-prescription-drug-reporting%20Orserdu.pdf)

<a id="topic-2.1.2.14-7"></a>

### Imlunestrant (Inluriyo): indications, regimen, EMBER-3 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication, monotherapy | “as monotherapy, for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy” |
| Indication, combination | “in combination with abemaciclib for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy” |
| Mechanism | “Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα.” |
| Recommended dosage | “The recommended dosage of INLURIYO, as monotherapy or in combination with abemaciclib, is 400 mg orally once daily until disease progression or unacceptable toxicity.” |
| Administration | “Take on an empty stomach at least 2 hours before food or 1 hour after food” |
| Dosage forms and strengths | “INLURIYO tablets contain 200 mg imlunestrant” |
| Pivotal trial | “The efficacy of INLURIYO was evaluated in EMBER-3 (NCT04975308), a randomized, open-label, active-controlled, multicenter trial that enrolled 874 adult patients with ER+, HER2- locally advanced or metastatic breast cancer of which 323 patients had ESR1 mutations (ESR1m), who were previously treated with an aromatase inhibitor either alone or in combination with a CDK4/6 inhibitor.” |
| Median PFS, ESR1m, INLURIYO (N=138), months (95% CI) | “5.5 (3.9, 7.4)” |
| Median PFS, ESR1m, fulvestrant or exemestane (N=118), months (95% CI) | “3.8 (3.7, 5.5)” |
| PFS hazard ratio, ESR1m (95% CI) | “0.62 (0.46, 0.82)” |
| Overall population | “A statistically significant difference in PFS in the overall population was not observed” |
| Median PFS, ESR1m, INLURIYO + abemaciclib (N=67) compared with INLURIYO (N=92), exploratory, months (95% CI) | “11.1 (7.4, 13.7)” “5.5 (3.8, 7.2)” |
| PFS hazard ratio, ESR1m, INLURIYO + abemaciclib compared with INLURIYO (95% CI) | “0.53 (0.35, 0.80)” |
| Warnings and precautions | “Embryo-Fetal Toxicity: INLURIYO can cause fetal harm.” |

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Imlunestrant (Inluriyo): wholesale acquisition cost

| Strength and dosage form | NDC | Pack size | Wholesale acquisition cost |
| --- | --- | --- | --- |
| 200 mg tablet | “0002-1717-28” | “28” | “$11,250.00” |
| 200 mg tablet | “0002-1717-56” | “56” | “$22,500.00” |

Source: [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf)

> “Lilly USA, LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.”
> “Accessed on 09/26/2025.”

Source: [Eli Lilly and Company Inluriyo WAC disclosure (2025)](https://pricinginfo.lilly.com/assets/pdf/Colorado_WAC_Disclosure_Sheet-Inluriyo.pdf)

<a id="topic-2.1.2.14-9"></a>

### Vepdegestrant (Veppanu): indication, regimen, VERITAC-2 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.” |
| Mechanism | “Vepdegestrant is a heterobifunctional protein degrader that binds to estrogen receptor (ER) and the E3 ligase cereblon (CRBN).” |
| Recommended dosage | “The recommended dosage of VEPPANU is 200 mg taken orally once daily with food” |
| Dosage forms and strengths | “Tablets: 100 mg and 200 mg” |
| Prior therapy required | “Patients were required to have disease progression on 1 to 2 prior lines of endocrine therapy, including 1 line with a CDK4/6 inhibitor.” |
| Exclusions | “Patients were excluded if they had received chemotherapy for advanced or metastatic disease or fulvestrant in any line of therapy” |
| Randomized comparison | “Patients were randomized 1:1 to receive VEPPANU 200 mg orally once daily (N=313), or fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and then once monthly thereafter (N=311).” |
| Median PFS, ESR1-mutated, VEPPANU (N=136), months (95% CI) | “5.0 (3.7, 7.4)” |
| Median PFS, ESR1-mutated, fulvestrant (N=134), months (95% CI) | “2.1 (1.9, 3.5)” |
| PFS hazard ratio, ESR1-mutated (95% CI) | “0.57 (0.42, 0.77)” |
| Warnings and precautions | “VEPPANU can cause QT (QTc) interval prolongation” “In VERITAC-2, QTc interval prolongation was reported in 10% of patients; Grade 3 occurred in 1.6% of patients.” |

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Camizestrant (Etcamah): indication, regimen, SERENA-6 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “ETCAMAH in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test” |
| Approval pathway | “This indication is approved under accelerated approval based on progression-free survival as measured from detection of ESR1 mutation” |
| Mechanism | “Camizestrant is an estrogen receptor (ER) antagonist.” |
| Recommended dosage | “The recommended dosage of ETCAMAH is 75 mg orally once daily, with or without food, until disease progression or unacceptable toxicity” |
| Dosage forms and strengths | “Tablets: 75 mg.” |
| Pivotal trial setting | “The ESR1 mutation status was assessed by ctDNA testing during first-line treatment with an AI in combination with a CDK4/6 inhibitor.” |
| Median PFS, ETCAMAH plus a CDK4/6 inhibitor (N = 157), months (95% CI) | “16.0 (12.7, 18.2)” |
| Median PFS, AI plus a CDK4/6 inhibitor (N = 158), months (95% CI) | “9.2 (7.2, 9.5)” |
| PFS hazard ratio (95% CI) | “0.44 (0.31, 0.60)” |
| Boxed warning | “ETCAMAH in combination with ribociclib, a QTc interval prolonging drug and a strong CYP3A inhibitor, or in combination with other QTc interval prolonging drugs, can increase the risk of Torsades de Pointes, other ventricular arrhythmias, and sudden death” |
| Warnings and precautions | “Bradycardia: Monitor heart rate more frequently during the first 30 days.” |

Source: [Etcamah prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220359Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

### Fulvestrant (Faslodex): indications, regimen, CONFIRM efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication, monotherapy after endocrine therapy | “HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.” |
| Indication, combination | “HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.” |
| Mechanism | “Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.” |
| Recommended dosage | “FASLODEX 500 mg should be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter.” |
| Dosage forms and strengths | “FASLODEX, an injection for intramuscular administration, is supplied as 250 mg/5 mL fulvestrant.” |
| Pivotal trial after endocrine therapy | “A randomized, double-blind, controlled clinical trial (CONFIRM, NCT00099437) was completed in 736 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease.” |
| PFS hazard ratio, 500 mg compared with 250 mg (95% CI) | “0.80 (0.68-0.94)” |
| Warnings and precautions | “Risk of Bleeding: Use with caution in patients with bleeding diatheses, thrombocytopenia, or anticoagulant use.” “Injection Site Reaction: Use caution while administering FASLODEX at the dorsogluteal injection site due to the proximity of the underlying sciatic nerve.” |

Source: [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

### Capivasertib (Truqap): indication, regimen, CAPItello-291 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-authorized test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.” |
| Mechanism | “Capivasertib is an inhibitor of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3) and inhibits phosphorylation of downstream AKT substrates.” |
| Recommended dosage | “The recommended dosage of TRUQAP, in combination with fulvestrant, is 400 mg orally twice daily (approximately 12 hours apart) with or without food, for 4 days followed by 3 days off.” |
| Dosage forms and strengths | “Tablets: 160 mg and 200 mg” |
| Pivotal trial | “The efficacy of TRUQAP with fulvestrant was evaluated in CAPItello-291 (NCT04305496), a randomized, double-blind, placebo-controlled, multicenter trial that enrolled 708 adult patients with locally advanced (inoperable) or metastatic HR-positive, HER2-negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) breast cancer of which 289 patients had tumors with eligible PIK3CA/AKT1/PTEN-alterations.” |
| Median PFS, altered tumors, TRUQAP with fulvestrant (N=155), months (95% CI) | “7.3 (5.5, 9.0)” |
| Median PFS, altered tumors, placebo with fulvestrant (N=134), months (95% CI) | “3.1 (2.0, 3.7)” |
| PFS hazard ratio, altered tumors (95% CI) | “0.50 (0.38, 0.65)” |
| Overall survival | “At the prespecified final analysis of OS, there was no significant difference in OS between the TRUQAP with fulvestrant arm and the placebo with fulvestrant arm, with HR 0.83 (95% CI: 0.63, 1.10) in the PIK3CA/AKT1/PTEN-altered subgroup.” |
| Warnings and precautions | “Hyperglycemia: TRUQAP can cause severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes.” “Diarrhea: TRUQAP caused diarrhea in most patients.” “Cutaneous Adverse Reactions: Monitor for signs and symptoms of cutaneous adverse reactions.” |

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.1.2.14-13"></a>

### Capivasertib: CAPItello-291 progression-free survival in the overall and AKT pathway-altered populations

> “In the overall population, the median progression-free survival was 7.2 months in the capivasertib–fulvestrant group, as compared with 3.6 months in the placebo–fulvestrant group (hazard ratio for progression or death, 0.60; 95% confidence interval [CI], 0.51 to 0.71; P<0.001).”
> “In the AKT pathway–altered population, the median progression-free survival was 7.3 months in the capivasertib–fulvestrant group, as compared with 3.1 months in the placebo–fulvestrant group (hazard ratio, 0.50; 95% CI, 0.38 to 0.65; P<0.001).”
> “Adverse events leading to discontinuation were reported in 13.0% of the patients receiving capivasertib and in 2.3% of those receiving placebo.”

Source: [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/)

<a id="topic-2.1.2.14-14"></a>

### Capivasertib (Truqap): wholesale acquisition cost of blister packs

| Product | NDC | Order quantity | WAC price |
| --- | --- | --- | --- |
| 160 mg tablets, 4 x 16 blister pack | “00310-9500-02” | “1 Blister Package (4x16)” | “$22,922.00” |
| 200 mg tablets, 4 x 16 blister pack | “00310-9501-02” | “1 Blister Package (4x16)” | “$22,922.00” |

Source: [AstraZeneca Truqap blister pack availability notice (2024)](https://associationdatabase.com/aws/MSHO/asset_manager/get_file/909026)

<a id="topic-2.1.2.14-15"></a>

### Gedatolisib (Revtorpyk): indication, regimen, VIKTORIA-1 efficacy, and warnings

| Attribute | Prescribing information |
| --- | --- |
| Indication | “REVTORPYK is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.” |
| Mechanism | “Gedatolisib is a kinase inhibitor of class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2, resulting in downstream inhibition of multiple effectors, including AKT.” |
| Recommended dosage | “The recommended dosage of REVTORPYK is 180 mg as an intravenous infusion over 30 minutes once weekly on Days 1, 8, and 15 of every 28-day cycle, in combination with fulvestrant, with or without palbociclib, until disease progression or unacceptable toxicity.” |
| Dosage forms and strengths | “REVTORPYK is supplied as a sterile, white to off-white lyophilized powder for injection containing 180 mg gedatolisib in a single-dose vial for reconstitution and further dilution.” |
| Prior therapy required | “All patients were required to have progression on or after treatment with a CDK4/6 inhibitor and a non-steroidal aromatase inhibitor (AI) therapy.” |
| Median PFS, REVTORPYK + fulvestrant + palbociclib (N=131), months (95% CI) | “9.3 (7.2, 16.6)” |
| Median PFS, REVTORPYK + fulvestrant (N=130), months (95% CI) | “7.4 (5.5, 9.9)” |
| Median PFS, fulvestrant (N=131), months (95% CI) | “2.0 (1.8, 2.3)” |
| Warnings and precautions | “REVTORPYK can cause severe stomatitis, including ulcers and oral mucositis.” “In Study 1 of VIKTORIA-1, stomatitis occurred in 72% of patients treated with REVTORPYK with fulvestrant and palbociclib, including Grade 3 events in 22% of patients.” “Hyperglycemia: REVTORPYK can cause severe hyperglycemia.” |

Source: [Revtorpyk prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219908Orig1s000lbl.pdf)

<a id="topic-2.1.2.14-16"></a>

### Gedatolisib: VIKTORIA-1 progression-free survival hazard ratios and discontinuation

> “The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant).”
> “Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients.”

Source: [Hurvitz et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13075786/)

<a id="topic-2.1.2.14-17"></a>

### Gedatolisib (Revtorpyk): wholesale acquisition cost

> “of REVTORPYK, which has been reported to the drug pricing compendia, is $10,000 per vial, or $30,000 per 28-day cycle of treatment.”

Source: [Celcuity Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1603454/000119312526450161/celc-20260930.htm)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
